Receptor Tyrosine Kinases

How an RTK fires

An RTK is structurally simple: an extracellular ligand-binding region, one membrane-spanning α-helix, and an intracellular tyrosine kinase domain followed by a regulatory tail. In the resting state the kinase is autoinhibited — the activation loop physically blocks the substrate cleft, and the receptor sits monomeric on the membrane.

The activation sequence has six unmistakable steps:

1. Ligand binding. EGF, VEGF, FGF, PDGF, insulin, or another growth factor binds the extracellular domain.
2. Dimerization. Two RTK molecules pair up — sometimes because the ligand itself is dimeric (PDGF), sometimes because the ligand bridges two receptors (FGF + heparan sulfate), sometimes because ligand binding exposes a dimerization arm (EGFR).
3. Trans-autophosphorylation. The two kinase domains, now neighbors, phosphorylate each other on a tyrosine in the activation loop. The kinase pops out of autoinhibition.
4. Tail phosphorylation. Once active, each kinase phosphorylates additional tyrosines on its partner's cytoplasmic tail. The tail becomes a bristle of phospho-Y "addresses."
5. Adaptor docking. SH2 and PTB domains in adaptor proteins (Grb2, Shc, PI3K-p85, PLC-γ, Src family kinases) recognize specific phospho-Y motifs by their flanking sequence and dock.
6. Cascade. Grb2-SOS launches Ras → Raf → MEK → ERK. PI3K turns PIP2 into PIP3, recruiting AKT. PLC-γ cleaves PIP2 into IP3 and DAG. Each branch runs in parallel.

Termination involves protein tyrosine phosphatases (especially PTP1B and SHP2) reversing the phosphorylations, ubiquitin ligases (Cbl) tagging activated receptors for endocytic degradation, and feedback phosphatases dampening downstream nodes.

Why RTKs matter

• Growth control. RTK signaling is the master regulator of cell proliferation; nearly every cancer dysregulates an RTK pathway somewhere.
• Metabolism. The insulin receptor is an RTK; type-2 diabetes is in part a defect in insulin-receptor → IRS → PI3K → AKT signaling.
• Angiogenesis. VEGFR drives blood-vessel growth; tumor neovascularization runs through it, and bevacizumab (anti-VEGF antibody) blocks the ligand.
• Development. FGFR mutations cause achondroplasia (FGFR3 G380R) and craniosynostosis syndromes; PDGFR mutations cause GIST (gastrointestinal stromal tumor).
• Drug design tractability. The ATP-binding pocket is a textbook small-molecule target; over 80 kinase inhibitors are FDA-approved.
• Mechanistic clarity. The dimerize → autophosphorylate → recruit logic is so clean that it became the prototype of "modular signaling" theory in 1990s cell biology.

The major RTK families

Family	Ligand(s)	Key adaptors	Disease relevance	Drugs
EGFR (ErbB1, HER1)	EGF, TGF-α, amphiregulin	Grb2, Shc, PLC-γ	Lung adenocarcinoma (L858R, exon 19 del); colorectal; head & neck	Gefitinib, erlotinib, osimertinib, cetuximab
HER2 (ErbB2)	None — orphan, obligate heterodimer	Same as EGFR	15-20% of breast cancers; gastric	Trastuzumab, lapatinib, T-DM1, T-DXd
VEGFR (1, 2, 3)	VEGF-A/B/C/D, PlGF	PLC-γ, PI3K, Shb	Tumor angiogenesis; macular degeneration	Sunitinib, sorafenib, axitinib, ramucirumab, bevacizumab (ligand)
FGFR (1-4)	FGFs (22 in humans) + heparan sulfate	FRS2 → Grb2	Achondroplasia (FGFR3); cholangiocarcinoma; bladder	Erdafitinib, pemigatinib, infigratinib
PDGFR (α, β)	PDGF-AA/BB/AB/CC/DD (dimeric ligands)	PI3K, PLC-γ, Src	GIST (also via KIT); dermatofibrosarcoma protuberans	Imatinib, sunitinib, regorafenib
Insulin receptor / IGF-1R	Insulin, IGF-1, IGF-2	IRS-1/2 → PI3K, Grb2	Type-2 diabetes; cancer cell survival	Insulin (replacement); IGF-1R mAbs (mostly failed)
Met (HGFR)	HGF / scatter factor	Gab1, PI3K, Grb2	Lung (MET exon 14 skipping); papillary RCC	Capmatinib, tepotinib, crizotinib
Trk (A/B/C)	NGF, BDNF, NT-3	PLC-γ, PI3K, Shc	NTRK fusions across many tumors; pain	Larotrectinib, entrectinib

Notice how every family has clinical drugs against it. The 2001 launch of imatinib (technically against the non-receptor BCR-ABL kinase, but using the same kinase-domain mechanism) opened a flood. Targeted RTK inhibition is now first-line therapy in lung, breast, GI, hematologic, and pediatric cancers.

Downstream pathways the phospho-Y addresses spawn

Pathway	Adaptor entry	Outcome	Pharmacology
Ras-Raf-MEK-ERK	Grb2-SOS via SH2	Proliferation, differentiation, transcription	BRAF inhibitors (vemurafenib), MEK inhibitors (trametinib)
PI3K-AKT-mTOR	p85 SH2 binds pY-X-X-M	Survival, cell-size growth, metabolism	Idelalisib, alpelisib, everolimus (mTOR)
PLC-γ → IP3 + DAG	PLC-γ SH2/SH3	Ca²⁺ release, PKC activation	No clinical PLC inhibitors; Ca²⁺ output is broad
STAT	Direct STAT SH2 docking	Cytokine-style transcription	JAK inhibitors (ruxolitinib) for related JAK-STAT receptors
Src-family kinases	SH2/SH3 of Src, Fyn, Yes	Cytoskeleton, focal adhesion, migration	Dasatinib (also BCR-ABL)
Cbl ubiquitin ligase	TKB domain reads pY	Receptor downregulation	Loss-of-function Cbl mutations cause juvenile myelomonocytic leukemia

Real-world consequences

• Gefitinib and the EGFR L858R story. Lung cancers with the L858R or exon-19 deletion mutation in EGFR are exquisitely sensitive to gefitinib — the activating mutation also makes the kinase preferentially bind the drug. Discovery of this in 2004 launched genotype-directed lung cancer treatment.
• T790M resistance. Most gefitinib responders relapse within a year, half due to T790M. Third-generation osimertinib was engineered to bind covalently to C797 alongside the methionine bulge. When osimertinib in turn fails, C797S is a common cause.
• HER2 amplification. Roughly one in six breast cancers overexpresses HER2 (often 50–100 copies per cell). Trastuzumab cut recurrence by half in HER2+ adjuvant trials and remains a textbook example of biomarker-driven therapy.
• Anti-angiogenics. Bevacizumab (anti-VEGF-A) and aflibercept (VEGF trap) starve tumors of blood supply. Ranibizumab and aflibercept also slow wet age-related macular degeneration by suppressing retinal VEGF.
• Achondroplasia. A single FGFR3 G380R substitution causes constitutive activation; the cartilage growth plate fails to elongate, producing the most common form of human dwarfism.
• Insulin resistance. In type-2 diabetes, serine phosphorylation of IRS-1 by stress kinases blunts the pY signal that PI3K reads, blocking GLUT4 translocation and glucose uptake.

Variants and special cases

• Insulin / IGF-1 receptors. Constitutively dimeric; signal through IRS scaffolds rather than direct receptor docking.
• Eph receptors. Bind membrane-bound ligands (ephrins) on neighboring cells; signal bidirectionally — both the Eph-bearing cell and the ephrin-bearing cell respond. Critical for axon guidance.
• Ret. Activated by GDNF-family ligands plus a GFRα co-receptor; constitutive activation by RET fusions or M918T point mutation drives medullary thyroid carcinoma and a fraction of NSCLC.
• ALK / ROS1. Rarely activated in normal adult tissue; pathologic activation almost always comes from gene fusions (EML4-ALK in lung). Crizotinib, alectinib, and lorlatinib treat them.
• Pseudokinases (HER3). HER3 is catalytically dead but a potent allosteric activator of HER2 in heterodimers. About 30% of human kinome members are pseudokinases — scaffolds masquerading as enzymes.
• Receptor cross-talk. EGFR is transactivated by GPCR signaling through metalloprotease-released HB-EGF; the two great signaling families do not stay in their lanes.

Common pitfalls and misconceptions

• "Phosphorylation activates the kinase directly." The activation-loop tyrosine phosphorylation merely relieves autoinhibition. The conformational change is the real switch.
• "All RTKs use Ras-MAPK." The ratio of MAPK : PI3K : PLC-γ activation varies dramatically — insulin receptor is mostly PI3K-AKT; FGFR is heavily MAPK; HER3 leans on PI3K because it is itself catalytically inactive.
• "Resistance means a new mutation in the same target." Often it is bypass — MET amplification rescues EGFR-inhibitor-treated cancers; KRAS or NRAS mutations bypass cetuximab in colorectal cancer.
• "More dimerization is always more signal." Some receptors (HER3) are signaling-dead alone but powerful as heterodimer partners; output depends on which two RTKs pair up.
• "Tyrosine kinases work the same as serine/threonine kinases." Tyrosine phosphorylation is rare (~0.05% of phospho-pool), specific, and read by a dedicated grammar of SH2/PTB domains. Serine/threonine has its own domains (14-3-3, BRCT, FHA) and its own logic.
• "Endocytosis turns RTK signaling off." Like GPCRs, internalized RTKs continue to signal from endosomes. The intracellular signaling output of EGFR is only partly switched off by endocytosis; degradation is what really stops it.